RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy

INTRODUCTION: Chemotherapeutic drugs are the main intervention for cancer management, but many drawbacks impede their clinical applications. Nanoparticles as drug delivery systems (DDSs) offer much promise to solve these limitations. OBJECTIVES: A novel nanocarrier composed of red blood cell (RBC)-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shu-Hui, Hsieh, Chia-Chu, Hsu, Szu-Chun, Yao, Ming, Hsiao, Jong-Kai, Wang, Shih-Wei, Lin, Chih-Peng, Huang, Dong-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Pharmaceutical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132207/
https://www.ncbi.nlm.nih.gov/pubmed/34026295
http://dx.doi.org/10.1016/j.jare.2020.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132207/
https://www.ncbi.nlm.nih.gov/pubmed/34026295
http://dx.doi.org/10.1016/j.jare.2020.11.009

Ejemplares similares